HIGH SURFACE-AREA LYOPHILIZED COMPOSITIONS COMPRISING ARSENIC FOR ORAL ADMINISTRATION IN PATIENTS
The present invention relates to treating malignancies such as tumors or cancers by orally administering lyophilized compositions comprising arsenic to a subject in such need. Malignancies include various hematological malignancies, such as acute myeloid leukemia (AML) including acute promyelocytic leukemia (APL), myelodysplastic syndrome (MDS), multiple myeloma (MM) and lymphomas and solid tumors including glioblastoma multiforme and breast cancer. This invention relates to a novel formulation comprising a lyophilized compositions comprising arsenic. The present invention also relates to a method for lyophilizing the arsenic trioxide, preparing the oral formulation comprising lyophilized compositions comprising arsenic, and a method for treating a subject with malignancies using the oral formulation.
1 . A solid, oral pharmaceutical composition, comprising:
arsenic trioxide in an amount of from about 1 mg to about 20 mg;
a surfactant; and
one or more pharmaceutically acceptable excipients.
2 . The solid, oral pharmaceutical composition of claim 1 , wherein the surfactant comprises sodium lauryl sulfate in an amount of from about 0.5 mg to about 10 mg.
3 . The solid, oral pharmaceutical composition of claim 2 , wherein the one or more pharmaceutically acceptable excipients comprises mannitol.
4 . The solid, oral pharmaceutical composition of claim 2 , wherein the one or more pharmaceutically excipients comprise talc, magnesium stearate, sodium chloride, or a combination thereof.
5 . The solid, oral pharmaceutical composition of claim 1 , wherein the arsenic trioxide is present in an amount of from about 1 mg to about 10 mg.
6 . The solid, oral pharmaceutical composition of claim 5 , wherein the surfactant comprises sodium lauryl sulfate in an amount of from about 0.5 mg to about 5 mg.
7 . The solid, oral pharmaceutical composition of claim 6 , wherein the one or more pharmaceutically acceptable excipients comprises mannitol.
8 . The solid, oral pharmaceutical composition of claim 6 , wherein the one or more pharmaceutically excipients comprise talc, magnesium stearate, or a combination thereof.
9 . The solid, oral pharmaceutical composition of claim 1 , wherein the arsenic trioxide is present in an amount of from about 1 mg to about 5 mg.
10 . The solid, oral pharmaceutical composition of claim 9 , wherein the surfactant comprises sodium lauryl sulfate in an amount of from about 0.5 mg to about 2.5 mg.
11 . The solid, oral pharmaceutical composition of claim 10 , wherein the one or more pharmaceutically acceptable excipients comprises mannitol.
12 . The solid, oral pharmaceutical composition of claim 10 , wherein the one or more pharmaceutically excipients comprise talc, magnesium stearate, or a combination thereof.
13 . A method for the treatment acute promyelocytic leukemia, which comprises administering to a patient in need thereof a therapeutically amount of a capsule or tablet comprising the pharmaceutical composition of claim 2 .
14 . The method of claim 13 , wherein the administering occurs once daily.
15 . The method of claim 13 further comprising administering to the patient a therapeutically effective amount of retinoic acid.
16 . A method for the treatment acute promyelocytic leukemia, which comprises administering to a patient in need thereof a therapeutically amount of a capsule or tablet comprising the pharmaceutical composition of claim 6 .
17 . The method of claim 16 , wherein the administering occurs once daily.
18 . The method of claim 16 further comprising administering to the patient a therapeutically effective amount of retinoic acid.
19 . A method for the treatment acute promyelocytic leukemia, which comprises administering to a patient in need thereof a therapeutically amount of a capsule or tablet comprising the pharmaceutical composition of claim 10 .
20 . The method of claim 19 , wherein the administering occurs once daily.
21 . The method of claim 19 further comprising administering to the patient a therapeutically effective amount of retinoic acid.
22 . The solid, oral pharmaceutical composition of claim 1 , wherein the arsenic trioxide is present in an amount of from about 1 mg to about 5 mg and the surfactant is present in amount of not more than about 50% by weight of the arsenic trioxide.
23 . The solid, oral pharmaceutical composition of claim 22 , wherein the one or more pharmaceutically excipients comprise mannitol, talc, magnesium stearate, sodium chloride, or a combination thereof.
24 . The solid, oral pharmaceutical composition of claim 22 , wherein the one or more pharmaceutically excipients comprise mannitol, talc, magnesium stearate, and sodium chloride.
25 . A method for the treatment acute promyelocytic leukemia, which comprises administering to a patient in need thereof a therapeutically amount of a capsule or tablet comprising the pharmaceutical composition of claim 22 .
26 . The method of claim 25 , wherein the administering occurs once daily.
27 . The method of claim 25 further comprising administering to the patient a therapeutically effective amount of retinoic acid.
28 . A method for the treatment acute promyelocytic leukemia, which comprises administering to a patient in need thereof a therapeutically amount of a capsule or tablet comprising the pharmaceutical composition of claim 24 .
29 . The method of claim 28 , wherein the administering occurs once daily.
30 . The method of claim 28 further comprising administering to the patient a therapeutically effective amount of retinoic acid.